RSS-Feed abonnieren

DOI: 10.1055/s-0045-1809888
Targeted Therapy in a Rare Spindle Cell Tumor with ETV6-NTRK3 Gene Fusion Rearrangement: A Case Report
Funding The authors declare that they did not receive funding from agencies in the public, private or non-profit sectors to conduct the present study.

Abstract
Introduction
Advances in genomic tools have significantly improved the classification of soft tissue tumors (STTs), enabling the identification of specific subsets characterized by recurrent fusions and genetic alterations involving the Raf-1 proto-oncogene, serine/threonine kinase (RAF1), B-Raf proto-oncogene, serine/threonine kinase (BRAF), and neurotrophic tyrosine receptor kinase (NTRK) genes. The present study aims to address the clinical challenge of diagnosing and managing a rare case of spindle cell tumor by examining the utility of molecular characterization, particularly focusing on NTRK rearrangements and their relationship with clinical outcomes. These tumors are defined by the coexpression of S100 and CD34 markers, lacking SOX-10 expression. Genetic changes can also be observed in STTs exhibiting spindle cell morphology, with fibroblastic or neural characteristics.
Case Description
The current report presents a rare case of a spindle cell tumor in a 15-year-old male patient. Comprehensive histopathological and molecular analyses revealed the tumor's distinct entity through the coexpression of S100 and CD34 markers and an unusual ETV6-NTRK3 gene rearrangement. The identification of the ETS variant transcription factor 6-neurotrophic receptor tyrosine kinase 3 (ETV6-NTRK3) gene fusion was critical for tailoring a personalized therapeutic approach using larotrectinib. Periodic imaging assessments during treatment demonstrated a significant tumor response, culminating in a complete metabolic response by fluorodeoxyglucose (FDG) positron-emission tomography-computed tomography (PET-CT).
Conclusion
This rare case underscores the importance of precise diagnostic criteria and advanced molecular testing in effectively managing rare STTs. The identification of the ETV6-NTRK3 rearrangement facilitated a successful personalized treatment strategy, highlighting the need for interdisciplinary collaboration in patient care. Integrating genomic insights into clinical practice is essential for managing complex spindle cell tumors and improving patient outcomes.
Ethical Approval
The present study, which was approved by the Human Research Ethics Committee at Hospital de Força Aérea do Galeão (HFAG) in Rio de Janeiro, Brazil (registration number CAAE 58431022.7.0000.5250), adhered strictly to Good Clinical Practice guidelines. Prior to any data collection, the participant provided written informed consent.
Data Availability
All data supporting the study findings are contained within the manuscript. Requests for additional data may be directed to the corresponding author.
Publikationsverlauf
Eingereicht: 30. Januar 2025
Angenommen: 10. April 2025
Artikel online veröffentlicht:
01. Juli 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
Jessé Lopes da Silva, Andréa Rodrigues Cordovil Pires, Priscilla de Almeida Romeiro, Felipe de Carvalho Caetano, Carolina de Bustamante Fernandes, Sumara Abdo Lacerda Matedi, Andréia Cristina de Melo. Targeted Therapy in a Rare Spindle Cell Tumor with ETV6-NTRK3 Gene Fusion Rearrangement: A Case Report. Brazilian Journal of Oncology 2025; 21: s00451809888.
DOI: 10.1055/s-0045-1809888
-
References
- 1 WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. In:
WHO classification of tumours. 5th ed. Vol. 3. Lyon: International Agency for Research
on Cancer; 2020
MissingFormLabel
- 2
Choi JH,
Ro JY.
The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities.
Adv Anat Pathol 2021; 28 (01) 44-58
MissingFormLabel
- 3
Rothermundt C,
Andreou D,
Blay JY,
Brodowicz T,
Desar IME,
Dileo P.
et al;
Writing committee on behalf of CSSS panellists.
Controversies in the management of patients with soft tissue sarcoma: Recommendations
of the Conference on State of Science in Sarcoma 2022. Eur J Cancer 2023; 180: 158-179
MissingFormLabel
- 4
Kallen ME,
Hornick JL.
The 2020 WHO Classification: What's New in Soft Tissue Tumor Pathology?. Am J Surg
Pathol 2021; 45 (01) e1-e23
MissingFormLabel
- 5
Suurmeijer AJH,
Dickson BC,
Antonescu CR.
Complementary value of molecular analysis to expert review in refining classification
of uncommon soft tissue tumors. Genes Chromosomes Cancer 2024; 63 (01) e23196
MissingFormLabel
- 6
Suurmeijer AJH,
Dickson BC,
Swanson D,
Zhang L,
Sung YS,
Cotzia P.
et al.
A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows
recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosomes Cancer
2018; 57 (12) 611-621
MissingFormLabel
- 7
Suurmeijer AJ,
Dickson BC,
Swanson D,
Zhang L,
Sung YS,
Huang HY.
et al.
The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements.
Genes Chromosomes Cancer 2019; 58 (11) 739-746
MissingFormLabel
- 8
Choi JH,
Ro JY.
The Recent Advances in Molecular Diagnosis of Soft Tissue Tumors. Int J Mol Sci 2023;
24 (06) 5934
MissingFormLabel
- 9
Riley DS,
Barber MS,
Kienle GS,
Aronson JK,
Von Schoen-Angerer T,
Tugwell P.
et al.
CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol
2017; 89: 218-235
MissingFormLabel
- 10
Yang H,
Yu L.
Cutaneous and Superficial Soft Tissue CD34+ Spindle Cell Proliferation. Arch Pathol Lab Med 2017; 141 (08) 1092-1100
MissingFormLabel
- 11
Nagasubramanian R,
Wei J,
Gordon P,
Rastatter JC,
Cox MC,
Pappo A.
Infantile Fibrosarcoma with NTRK3-ETV6 Fusion Successfully Treated with the Tropomyosin-Related
Kinase Inhibitor LOXO-101. Pediatr Blood Cancer 2016; 63 (08) 1468-1470
MissingFormLabel
- 12
Chiang S,
Cotzia P,
Hyman DM,
Drilon A,
Tap WD,
Zhang L.
et al.
NTRK Fusions Define a Novel Uterine Sarcoma Subtype with Features of Fibrosarcoma.
Am J Surg Pathol 2018; 42 (06) 791-798
MissingFormLabel
- 13
Davis JL,
Lockwood CM,
Albert CM,
Tsuchiya K,
Hawkins DS,
Rudzinski ER.
Infantile NTRK-associated Mesenchymal Tumors. Pediatr Dev Pathol 2018; 21 (01) 68-78
MissingFormLabel
- 14
Yamazaki F,
Nakatani F,
Asano N,
Wakai S,
Sekimizu M,
Mitani S.
et al.
Novel NTRK3 Fusions in Fibrosarcomas of Adults. Am J Surg Pathol 2019; 43 (04) 523-530
MissingFormLabel
- 15
Davis JL,
Lockwood CM,
Stohr B,
Boecking C,
Al-Ibraheemi A,
DuBois SG.
et al.
Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. Am J Surg
Pathol 2019; 43 (04) 435-445
MissingFormLabel
- 16
Kovalenko I,
Roy P,
Soni B,
Sangha L,
Toom S.
Secretory Carcinoma of the Breast Mimicking Invasive Ductal Carcinoma: A Case Report.
Am J Case Rep 2022; 23: e936665
MissingFormLabel
- 17
Gong LH,
Liu WF,
Niu XH,
Ding Y.
Two cases of spindle cell tumors with S100 and CD34 co-expression showing novel RAF1
fusions. Diagn Pathol 2022; 17 (01) 80
MissingFormLabel
- 18
Hung YP,
Fletcher CDM,
Hornick JL.
Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like
neural tumour and histological mimics. Histopathology 2018; 73 (04) 634-644
MissingFormLabel
- 19
Abs D,
Landman S,
Osio A,
Lepesant P,
Schneider P,
Obadia D.
et al.
Spindle cell tumor with CD34 and S100 co-expression and distinctive stromal and perivascular
hyalinization showing EML4-ALK fusion. J Cutan Pathol 2021; 48 (07) 896-901
MissingFormLabel
- 20
Shreenivas A,
Janku F,
Gouda MA,
Chen HZ,
George B,
Kato S,
Kurzrock R.
ALK fusions in the pan-cancer setting: another tumor-agnostic target?. NPJ Precis
Oncol 2023; 7 (01) 101
MissingFormLabel
- 21
Michal M,
Ptáková N,
Martínek P,
Gatalica Z,
Kazakov DV,
Michalová K.
et al.
S100 and CD34 positive spindle cell tumor with prominent perivascular hyalinization
and a novel NCOA4-RET fusion. Genes Chromosomes Cancer 2019; 58 (09) 680-685
MissingFormLabel